Table 1.
Patient characteristics and MRI measures, Dutch cohort.
| All (n = 120) | RR (n = 50) | SP (n = 27) | PP (n = 13) | NINDC (n = 23) | INDC (n = 7) | |
|---|---|---|---|---|---|---|
| M:F | 56:64 | 19:31 | 15:12 | 8:5 | 10:13 | 4:3 |
| Age (years) | 45.5 ± 11.0 | 41.4 ± 9.6 | 49.6 ± 7.6 | 50.4 ± 5.3 | 47.5 ± 15.1 | 43.3 ± 15.1 |
| EDSS | – | 3.0 (2.5–4) | 6.0 (4–7) | 4.0 (3.5–6) | – | – |
| Disease duration (years) | 6.5 (2.3–6.5) | 6.5 (2.9–13.7) | 19.3 ± 8.7 | 10.2 (3.8–19.7) | 1.14 (0.3–2.8) | 0.07 (0.02–2.8) |
| DMT:NODMT | – | 19:31 | 4:23 | 0:0 | – | – |
| T2LV | – | 2.79 (0.99–9.23) | 7.59 (3.67–15.23) | 3.73 (1.19–9.62) | – | – |
| BHLV | – | 0.14 (0.06–0.41) | 0.39 (0.06–1.56) | 0.53 (0.15–2.92) | – | – |
| NBV | – | 1.25 (1.16–1.31) | 1.16 (1.10–1.21) | 1.27 (1.17–1.34) | – | – |
| Gado+ | – | 8:33 | 4:23 | 2:8 | – | – |
All: all subjects; BHLV: black hole lesion volume; MRI: magnetic resonance imaging; DMT: disease-modifying treatment; EDSS: Expanded Disability Status Scale; F: female; Gado+: gadolinium-enhanced lesions; INDC: inflammatory neurologic disease controls; IQR: interquartile range; M: male; n: number of subjects; NBV: normal brain volume; NINDC: non-inflammatory neurologic disease controls; NODMT: no use of disease-modifying treatment; PP: primary progressive; RR: relapsing-remitting; SD: standard deviation; SP: secondary progressive; T2LV: T2 lesion volume.
Values are reported as mean ± SD or median (IQR) (Dutch cohort).